证券代码：002675 证券简称：东诚药业 公告编号：2024-043 2、SSTR2 是一种 G 蛋白偶联受体（GPCR），主要与生长抑素（Somatostatin） 结合，参与调节多种激素，包括生长激素、胰岛素和胃肠激素的分泌。NETs 在 烟台东诚药业集团股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 5 月 23 日，烟台东诚药业集团股份有限公司（以下简称"公司"或 "上市公司"）控股子公司烟台蓝纳成生物技术有限公司（以下简称"蓝纳成"） 收到中国国家药品监督管理局（以下简称"国家药监局"）核准签发的关于 177Lu- LNC1010 注射液的药物临床试验批准通知书，将于近期开展临床试验。 | | | | 药物名称 | 177Lu-LNC1010 注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | 受理号 | CXHL2400286 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查， | | | 你公司提 ...

Summary of the Conference Call for Dongcheng Pharmaceutical Company Overview - **Company**: Dongcheng Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on nuclear medicine and related products Key Points and Arguments 1. **Financial Performance**: - The company reported a decline in revenue for Q1 2024 compared to Q1 2023, primarily due to price trends in Gansu, which saw a decrease in prices starting from Q1 2023 [2][3] - Despite revenue pressure, profit margins remained stable, indicating effective cost management [3][5] 2. **Market Trends**: - The price of steel wire and ammonium sulfate has stabilized and is expected to improve in the second half of the year, contrasting with the previous year's downward trend [3][4] - The company anticipates a positive trend in Gansu's market, with expectations of price stability and potential increases in the latter half of 2024 [15][16] 3. **Product Development**: - The company is progressing with its nuclear medicine products, particularly the FDG (Fluorodeoxyglucose) segment, which is expected to show improvement in sales in the upcoming months [4][5] - A new product, a targeted therapy for myocardial function assessment, is in the main review stage and is expected to be approved in the first half of 2024 [9][12] 4. **Regulatory and Market Approval**: - The company submitted an NDA for a new product in late 2023, with expectations for approval and market entry by mid-2024 [9][27] - The company is actively engaging in academic promotion and establishing sales channels for new products [10][12] 5. **Sales and Marketing Strategy**: - The company is focusing on enhancing its sales and marketing strategies, particularly in the nuclear medicine sector, to ensure effective product distribution and market penetration [52][55] - There is an emphasis on building a comprehensive distribution network to support the delivery of nuclear medicines [50][51] 6. **Research and Development**: - Ongoing R&D efforts are aimed at expanding the product pipeline, with several products in various stages of clinical trials [17][22] - The company is exploring innovative treatment combinations and is positioned to leverage its R&D capabilities to meet market demands [20][22] 7. **Market Potential**: - The company sees significant market potential for its products, particularly in the context of increasing cancer prevalence in China, which could drive demand for its innovative therapies [21][33] - The expected market size for certain products is projected to reach several billion dollars, indicating strong growth prospects [31][33] 8. **Challenges and Risks**: - The company faces challenges related to price pressures in the Gansu region and the overall impact of market fluctuations on revenue [13][44] - Regulatory hurdles and the competitive landscape in the pharmaceutical industry pose risks to timely product launches and market share [35][44] Additional Important Information - The company is actively working on integrating its diagnostic and therapeutic offerings to create a comprehensive healthcare solution [39][55] - There is a focus on enhancing the clinical and operational capabilities of its nuclear medicine facilities to meet growing demand [56][59] - The company is also exploring partnerships and collaborations to expand its market reach and enhance its product offerings [34][35]

Summary of the Conference Call for Dongcheng Pharmaceutical Company Overview - The conference call was held by Dongcheng Pharmaceutical on May 23, 2024, facilitated by China International Capital Corporation (CICC) [7][8]. Key Points Discussed Financial Performance - Dongcheng Pharmaceutical reported a decline in revenue for Q1 2024 compared to Q1 2023, primarily due to price trends in Gansu [8][9]. - The price of products in Gansu has been stable since Q1 2024, which is expected to stabilize further in the coming months [9][10]. - The company anticipates a better performance in the second half of 2024 compared to Q3 2023, despite facing pressure on absolute income due to the impact of centralized procurement [11][12]. Product Updates - The company is optimistic about the sales of its key products, particularly in the nuclear medicine sector, with expectations of significant improvements in sales for FDG and other related drugs in the upcoming months [13][14]. - Dongcheng has submitted a product for approval that is currently in the main review stage at the CDE, with hopes for approval in the first half of 2024 [18][19]. Market Trends - The company noted an increase in export volumes from Gansu, despite a decrease in prices, indicating a potential recovery in demand [22][23]. - The management expects that the price trends will not decline further and may even show an upward trend in the second half of 2024 [24][25]. R&D and Future Products - Dongcheng is making progress in its R&D efforts, with several products entering different clinical trial phases [16][30]. - The company is focusing on developing innovative treatments, particularly in the field of targeted therapies for cancer, with promising market potential [26][29]. Strategic Initiatives - Dongcheng is enhancing its collaboration efforts and financing strategies to support its product pipeline and market expansion [16][30]. - The company is also working on building a comprehensive supply chain and distribution network to improve its operational efficiency [56][57]. Challenges and Risks - The company acknowledged the volatility in its earnings over the past two years, primarily due to the impacts of the COVID-19 pandemic and changes in the healthcare reimbursement landscape [50][51]. - There are ongoing concerns regarding the pricing pressures in the Gansu region and the overall market dynamics affecting revenue stability [50][52]. Additional Insights - The management emphasized the importance of maintaining a robust pipeline of products and the need for strategic partnerships to navigate the competitive landscape [41][42]. - Dongcheng is also exploring opportunities in international markets and potential collaborations to enhance its product offerings [41][42]. This summary encapsulates the key discussions and insights from the conference call, highlighting the company's current status, market outlook, and strategic initiatives.

证券代码：002675 证券简称：东诚药业 公告编号：2024-042 烟台东诚药业集团股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决提案的情形。 2.本次股东大会未涉及变更前次股东大会决议。 一、会议召开情况 （一）召开时间： 现场会议时间：2024年5月17日（星期五）14:30； 网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为： 2024年5月17日9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2024年5月17日9:15-15:00期间的任意时间。 （二）现场会议地点：烟台经济技术开发区长白山路7号公司会议室； （六）本次股东大会的召集、召开程序符合《公司法》《上市公司股东大会 规则》等法律、法规、规范性文件和《公司章程》的规定。 二、会议出席情况 参加本次会议的股东及股东代理人共24人，代表公司有表决权的股份 237,642,899股，占公司有表决权股份总数的28.8193%。 ...

北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于烟台东诚药业集团股份有限公司 2023 年度股东大会的 法律意见书 致：烟台东诚药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等规定， 北京市中伦律师事务所（以下简称本所）接受烟台东诚药业集团股份有限公司（以 下简称公司）的委托，指派本所律师对公司 2023 年度股东大会（以下简称本次 股东大会）进行见证并就相关事项出具本法律意见书。 为出具本法律意见书，本所律师查阅了公司提供的相关文件，包括但不限于： 1. 现行《烟台东诚药业集团股份有限 ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-041 河北安迪科本次被认定"专精特新"中小企业，是对其创新能力、技术实力、 产品质量、服务水平、专业化程度等综合发展实力的充分认可，有利于提升公司 的品牌形象，对公司的长远发展具有积极作用。 本次"专精特新"认定不会对公司当期经营业绩产生重大影响，敬请广大投 资者谨慎决策，注意投资风险。 三、备查文件 河北省工业和信息化厅关于公布 2024 年第一批河北省专精特新中小企业 名单的通知 烟台东诚药业集团股份有限公司 关于下属公司被认定为河北省专精特新中小企业的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 根据《河北省工业和信息化局关于公布 2024 年第一批河北省专精特新中小 企业名单的通知》，烟台东诚药业集团股份有限公司（以下简称"公司"）下属公 司河北安迪科正电子技术有限公司（以下简称"河北安迪科"）被认定为河北省 "专精特新"中小企业。 二、对公司的影响 "专精特新"是指具备"专业化、精细化、特色化、新颖化"特征的中小企 业，旨在培育一批在细分行业内技术实力强、产品质量 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][8]. Core Views - The company reported a revenue of 3.276 billion yuan in 2023, a year-on-year decrease of 8.58%, and a net profit attributable to shareholders of 210 million yuan, down 31.75% year-on-year. The decline in performance is primarily attributed to asset impairment provisions totaling 90 million yuan in 2023. In Q1 2024, the company achieved a revenue of 647 million yuan, representing a year-on-year increase of 23.90%, and a net profit of 64 million yuan, up 28.38% year-on-year [1]. - Financial metrics for 2023 include a gross margin of 44.87% (up 1.93 percentage points), a net margin of 7.76% (down 2.09 percentage points), and a research and development expense ratio of 6.02% (up 1.46 percentage points). In Q1 2024, the gross margin was 43.79% (down 3.65 percentage points), while the net margin improved to 10.19% (up 2.79 percentage points) [1]. - The nuclear medicine segment generated revenue of 1.017 billion yuan in 2023, an increase of 11.2% year-on-year, with key products like 18F-FDG contributing 420 million yuan (up 12%) and Y-90 labeled drugs generating 100 million yuan (down 3.23%). The raw material drug segment saw revenue of 1.678 billion yuan (up 18.61%), while the formulation segment declined to 400 million yuan (down 17.20%) [1]. - The company is focused on the nuclear medicine sector, with several products in clinical registration stages, including LNC1001 for prostate cancer and 99mTc-GSA for liver function diagnosis, which is preparing for market registration [1]. - Earnings forecasts for 2024-2026 predict EPS of 0.36, 0.45, and 0.53 yuan, corresponding to PE ratios of 37.33, 29.83, and 25.53 times, respectively [1]. Financial Summary - In 2023, the company reported a gross profit margin of 44.87% and a net profit margin of 7.76%. The gross profit margin is expected to decrease to 43.79% in Q1 2024, while the net profit margin is projected to increase to 10.19% [1]. - The company’s total assets were reported at 8.529 billion yuan, with a net asset value of 5.008 billion yuan [7]. - The projected revenue growth rates for 2024-2026 are 0.1%, 9.5%, and 13.2%, respectively, with net profit growth rates of 41.8%, 25.1%, and 16.8% [14].

Investment Rating - The report maintains a "Buy" rating for the company [26]. Core Views - The company's performance in 2023 declined due to multiple negative factors, including reduced demand for raw materials from downstream heparin formulation companies, leading to a provision for inventory impairment of 112 million yuan for heparin sodium raw materials. The raw material business revenue was 1.678 billion yuan, down 18.61%, with a gross margin of 26.10%, and heparin sodium sales volume decreased by 11.79%. The formulation product revenue was 400 million yuan, down 17.20%, primarily due to price declines following the centralized procurement of nadroparin calcium injection in March 2023. However, the nuclear medicine business performed well, with total revenue of 1.017 billion yuan, up 11.20%, driven by key products like 18F-FDG and Yunk injection [2][5]. Financial Summary - In 2023, the company achieved total revenue of 3.276 billion yuan, a decrease of 8.58%, and a net profit attributable to shareholders of 210 million yuan, down 31.75%. The first quarter of 2024 saw revenue of 647 million yuan, down 23.90%, but net profit attributable to shareholders increased by 28.38% to 64.33 million yuan [5][6]. - Revenue projections for 2024 to 2026 are 3.291 billion yuan, 3.616 billion yuan, and 4.009 billion yuan, with year-on-year growth rates of 0.5%, 9.9%, and 10.9%, respectively. Net profit attributable to shareholders is expected to be 305 million yuan, 364 million yuan, and 436 million yuan, with growth rates of 45.7%, 19.1%, and 19.9% [6][17]. Market Position and Future Outlook - The company is advancing its innovative nuclear medicine research, with several new products at various stages of development. Products like 99mTc-labeled tecfidera and sodium fluoride injection have submitted for market approval, while others are in clinical trials. The next 2-3 years are expected to see a concentration of product approvals, which could lead to rapid market expansion due to the established supply network [14].

Investment Rating - The report maintains a "Buy" rating for the company, considering the scarcity of its nuclear medicine assets [10]. Core Views - The company's performance in 2023 was impacted by the cyclical fluctuations in heparin raw materials and centralized procurement, while the nuclear medicine business remains stable and shows potential for future growth [1]. - Significant investment in research and development is being made to drive innovation in nuclear medicine, with a focus on integrating resources to enhance product development [1]. Summary by Relevant Sections Financial Performance - In 2023, the company achieved operating revenue of 3.276 billion yuan, a decrease of 8.58% year-on-year, and a net profit attributable to shareholders of 210 million yuan, down 31.75% year-on-year [2]. - For Q1 2024, the company reported operating revenue of 647 million yuan, a decline of 23.90% year-on-year, while net profit attributable to shareholders increased by 28.38% to 64 million yuan [1]. - The revenue breakdown for 2023 shows nuclear medicine sales at 1.017 billion yuan, up 11.20% year-on-year, while raw material sales were 1.678 billion yuan, down 18.61% due to low global demand [1]. Research and Development - The company invested 313 million yuan in R&D in 2023, a year-on-year increase of 77.23%, with 76.73% of this investment directed towards nuclear medicine [1]. - Key products in development include various nuclear medicine injections, with some currently in Phase III clinical trials [1]. Profit Forecast and Valuation - The profit forecast for 2024 and 2025 has been revised down to 306 million yuan and 366 million yuan, respectively, reflecting a decrease of 39% and 41% from previous estimates [1]. - The projected net profit for 2026 is 430 million yuan, with corresponding price-to-earnings ratios of 37, 31, and 27 for the years 2024, 2025, and 2026, respectively [1].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002675 证券简称：东诚药业 公告编号：2024-040 2024 年 5 月 2 日，烟台东诚药业集团股份有限公司（以下简称"公司"）下 属公司 LNC PHARMA PTE. LTD.（以下简称"LNC"）收到美国食品药品监督管 理局（以下简称"FDA"）核准签发的关于 18F-LNC1007 注射液的药品临床试验 批准通知书 (Study May Proceed Letter，以下简称"SMP")，将于近期在澳大利 亚开展 I 期临床试验。 烟台东诚药业集团股份有限公司 关于下属公司获得药物临床试验批准通知书的公告 目前国内外暂无同产品上市，亦无相关销售数据。 截至目前，18F-LNC1007 注射液相关项目累计已投入研发费用约 1,195.47 万 元。 三、风险提示 现将 18F-LNC1007 注射液相关情况公告如下： | 药物名称 | 18F-LNC1007 注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 临床试验 | | IND 号 | 17004 ...